Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RecruitingPhase 4Healthy volunteers welcome
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Age\>=18 years * HIV Diagnosis * On Antiretroviral Therapy with HIV Viral Load\<200 within last year Exclusion Criteria: * Other significant immunosuppressing condition * Age\< 18 years * Pregnancy (at enrollment) * Contraindication to pneumococcal vaccination * Known contraindication to non-clinical blood draws (severe anemia last hemoglobin \<8g/dl) * Subjects who, in the opinion of the Investigator, may be non-adherent to study schedules or procedures. * Adults unable to consent * Individuals with impaired ability to consent * Incarceration at time of enrollment Controls inclusion criteria: * Age\>=18 years * HIV Ag-Ab test negative
About the study
This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.
What is being tested
- Conjugate Pneumococcal Vaccine 20 (PCV20) (biological)
Sponsor: Hennepin Healthcare Research Institute · Participants: 250 · Started: Jul 8, 2024
Contact the study team
- Anne Frosch, MD · Phone: (612)-283-4349
- Marya Abd El Hadi, BSc · Phone: (612)-873-6252
Official record on ClinicalTrials.gov — NCT06514547
Locations in the U.S.
| Minnesota | Hennepin Healthcare System, Minneapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.